Register for our webinar!
As personalized medicine advances in cancer treatment, reliable preclinical models are essential. Inotiv's B-NDG mouse model offers a unique solution, bridging the gap between preclinical research and effective therapies.
The B-NDG strain is a highly immunodeficient model lacking T, B, and NK cells. This makes it ideal for generating humanized models and studying human immune cell functions. With reduced "leakiness" and a lack of immune system, B-NDG mice enable improved engraftment of human cells, tissues, and tumors.
Widely used in preclinical studies, B-NDG mice are particularly valuable for generating tumor xenografts, including PDX (Patient-Derived Xenografts) and CDX (Cell-Line Derived Xenografts), and are essential for precision medicine research. B-NDG mice's ability to maintain long-term engraftment and tumor growth contributes to a deeper understanding of cancer treatment approaches.
Presented by:
Dr. Jiyan Mohammad
Lead Scientist/Senior Operations Manager
Tumor Models & Services
Antibody Production and Purification Services
Date:
Wednesday, May 28, 2025 at 14:00 pm CET
Dr. Jiyan Mohammad is an oncology expert with over 10 years of experience driving cancer research utilizing animal models. As a Lead Scientist and Senior Operations Manager for Tumor Models Service, Antibody Production and Purification Services at Inotiv, a global leader in preclinical research, Dr. Mohammad leads a team of 12 dedicated scientists focused on preclinical studies.
